Literature DB >> 35796732

Exploring definitions of retention in care for people living with HIV in the United States in the modern treatment era.

Catherine R Lesko1, Michael J Mugavero2, Nicola M Shen1, Anthony T Fojo3, Richard D Moore3, Jeanne C Keruly3, Edward R Cachay4, Sonia Napravnik5,6, Kenneth H Mayer7,8,9, Katerina A Christopoulos10, Jeffrey M Jacobson11, Peter F Rebeiro12, Geetanjali Chander3.   

Abstract

OBJECTIVE: To describe retention in HIV care based on various definitions of retention in the modern treatment era.
DESIGN: A cohort study of people enrolled in care at seven mostly urban HIV clinics across the United States, 2010-2018.
METHODS: We estimated retention based on missed visits, kept visits, kept encounters (clinical visits, CD4 counts, and viral loads), and HIV labs. We contrasted risk factors for retention by different definitions and estimated odds ratios for of viral suppression and hazard ratios for mortality in 2 years immediately following the year in which retention was defined (the study year).
RESULTS: Across 108 171 person-years (N = 21 481 people), in 71% of years people kept ≥75% of scheduled visits; in 78%, people kept ≥2 visits >90 days apart; in 74%, people had ≥2 HIV labs >90 days apart; and in 47%, people had no gaps >6 months in clinic visits. Missing >25% of scheduled visits despite attending ≥2 visits >90 days apart was associated with nonwhite non-Hispanic race/ethnicity, history of injection drug use, and prior AIDS diagnosis. In contrast, attending ≥75% of scheduled visits while not attending ≥2 visits >90 days apart was associated with male sex, white race, no injection drug use history, and no prior AIDS diagnosis. Subsequent viral nonsuppression was more strongly associated with missed- than kept-visit measures of retention; 2-year mortality was only associated with failure to be retained by missed-visit measures. DISCUSSION: Missed and kept-visit definitions of retention capture different constructs. Missed-visit measures are more strongly associated with poor HIV outcomes.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35796732      PMCID: PMC9273016          DOI: 10.1097/QAD.0000000000003232

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  25 in total

1.  Mixed models for assessing correlation in the presence of replication.

Authors:  Anthony Hamlett; Louise Ryan; Paulina Serrano-Trespalacios; Russ Wolfinger
Journal:  J Air Waste Manag Assoc       Date:  2003-04       Impact factor: 2.235

2.  Jurisdiction level differences in HIV diagnosis, retention in care, and viral suppression in the United States.

Authors:  Kristen Mahle Gray; Stacy M Cohen; Xiaohong Hu; Jianmin Li; Jonathan Mermin; H Irene Hall
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

3.  Use of multiple data sources and individual case investigation to refine surveillance-based estimates of the HIV care continuum.

Authors:  Julia C Dombrowski; Susan E Buskin; Amy Bennett; Hanne Thiede; Matthew R Golden
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

4.  Human immunodeficiency virus transmission at each step of the care continuum in the United States.

Authors:  Jacek Skarbinski; Eli Rosenberg; Gabriela Paz-Bailey; H Irene Hall; Charles E Rose; Abigail H Viall; Jennifer L Fagan; Amy Lansky; Jonathan H Mermin
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

5.  Racial disparities in HIV virologic failure: do missed visits matter?

Authors:  Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan Davies; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

6.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

7.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Melanie A Thompson; Paul E Sax; Davey M Smith; Constance A Benson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2020-10-27       Impact factor: 56.272

8.  Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Melanie A Thompson; Michael A Horberg; Allison L Agwu; Jonathan A Colasanti; Mamta K Jain; William R Short; Tulika Singh; Judith A Aberg
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

9.  Strong agreement of nationally recommended retention measures from the Institute of Medicine and Department of Health and Human Services.

Authors:  Peter F Rebeiro; Michael A Horberg; Stephen J Gange; Kelly A Gebo; Baligh R Yehia; John T Brooks; Kate Buchacz; Michael J Silverberg; John Gill; Richard D Moore; Keri N Althoff
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

10.  Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators.

Authors:  Jessie K Edwards; Stephen R Cole; Daniel Westreich; Richard Moore; Christopher Mathews; Elvin Geng; Joseph J Eron; Michael J Mugavero
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more
  1 in total

1.  Longitudinal HIV care outcomes by gender identity in the United States.

Authors:  Catherine R Lesko; Jessie K Edwards; David B Hanna; Angel M Mayor; Michael J Silverberg; Michael Horberg; Peter F Rebeiro; Richard D Moore; Ashleigh J Rich; Kathleen A McGinnis; Kate Buchacz; Heidi M Crane; Charles S Rabkin; Keri N Althoff; Tonia C Poteat
Journal:  AIDS       Date:  2022-07-21       Impact factor: 4.632

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.